The Hatch-Waxman Act of 1984 created the modern U.S. generic drug system, balancing innovation incentives with affordable access. It cut approval costs, sped up generic entry, and saved trillions - but also opened doors to patent manipulation.
The 30-month stay under the Hatch-Waxman Act delays generic drug approval by freezing FDA action during patent lawsuits. While meant to protect innovation, it's often used to extend monopolies, costing patients billions annually.